|
|
|
Michael Rossi, chief executive officer, Y-mAbs Therapeutics | The radiotherapy company's novel SADA construct uses self-assembling tetramers to deliver isotopes directly to cancer cells for a highly targeted, less toxic treatment. | |
|
|
|
By Foteini Michalopoulou, Imperial College London | Data-driven, hybrid modeling complements mechanistic thinking by reducing computational load for faster decision-making when time is a critical consideration. | |
|
|
|
By V. Klyushnichenko, Calibr-Skaggs Institute for Innovative Medicines | This emerging class brings substantial formulation challenges beyond those of traditional mAbs. Here’s a comprehensive look at the issues and some solutions. | |
|
|
|
|
|
|
|
|
|
